Share This Page
Histamine-1 Receptor Inhibitor Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Histamine-1 Receptor Inhibitor
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Pharms Ltd | ZADITOR | ketotifen fumarate | SOLUTION/DROPS;OPHTHALMIC | 077200-001 | Sep 2, 2008 | OTC | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glenmark Speclt | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Glenmark Speclt | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Glenmark Speclt | RYALTRIS | mometasone furoate; olopatadine hydrochloride | SPRAY, METERED;NASAL | 211746-001 | Jan 13, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Histamine-1 (H1) Receptor Inhibitor Drugs: Exclusivity, Orange Book Status, and Generic Entry Risk
What patents protect first- and second-generation H1 receptor inhibitors?
Answer: For most H1 inhibitors, the core active-ingredient patents are expired in major markets; current patent leverage usually comes from (1) reformulations (extended release, orally disintegrating, transdermal, nasal, ophthalmic), (2) fixed-dose combinations, and (3) specific method-of-use and, less frequently, new salts/polymorphs.
Which H1 inhibitors dominate the commercial landscape?
Common marketed H1 receptor inhibitors (systemic unless stated) include first generation (for allergy/itch/sedation) and second generation (less CNS penetration):
- Cetirizine (including combinations)
- Levocetirizine
- Loratadine
- Desloratadine
- Fexofenadine
- Rupatadine
- Bilastine
- Azelastine (nasal, antihistamine with additional activity profile)
- Olopatadine (ophthalmic)
- Ketotifen (systemic and ophthalmic; broader mast-cell activity)
How does patent coverage typically split across H1 products?
Patent estate layers that still matter commercially:
- Formulation patents
- Extended-release tablets/capsules, orally disintegrating tablets, fast-dissolve, or improved solubility.
- Examples of common protection strategies: controlled-release matrix, particle engineering, coating and release profiles, and taste-masking for pediatric use.
- Salt polymorph and solid-state patents
- New salts or polymorphs can extend exclusivity for line-extensions, but enforceability depends on jurisdiction and claim scope.
- Combination patents
- Fixed-dose pairings (H1 + decongestant, H1 + antileukotriene, H1 + intranasal steroid).
- Combination claims can block “authorized generic” style launches even after monotherapy ingredient patents expire.
- Method-of-use patents
- Specific dosing regimens, pediatric indications, or symptom-based use (itch, allergic rhinitis subpopulations).
- Enforceability depends on whether the labeled regimen aligns with the claims and whether generic labels induce infringement.
Market reality: Most “classic” H1 ingredient patents are long expired. Generic competition is intense; therefore, formulation and combination claims drive remaining exclusivity windows.
When do H1 antihistamines lose exclusivity in the US and EU?
Answer: Exclusivity varies by product line. Most ingredient exclusivity in the class is already expired, with remaining exclusivity driven by specific reformulations and combination products. For US products, the controlling timing is usually the last Orange Book-listed patent and any unexpired periods of exclusivity under FDCA (including pediatric exclusivity, where applicable).
US timing framework used for H1 generic entry
- Orange Book listings control Paragraph IV viability
- Generic applicants file certifications against each listed patent: ANDA “Paragraph IV” targets specific patents.
- 180-day exclusivity incentives
- If a first Paragraph IV filer prevails, the 180-day exclusivity can deter immediate competitive launches.
EU timing framework used for H1 generic entry
- Supplementary Protection Certificates (SPCs) can extend patent protection for active ingredients (where eligible).
- Reformulation SPCs are less common; combination products typically depend on their component patents and any applicable SPCs.
Commercial implication: In an intensely generic-heavy class, the practical barrier is not the earliest ingredient expiration date but the presence of enforceable reformulation or combination patents listed in the Orange Book for the marketed strength and dosage form.
What is the Orange Book status of common H1 receptor inhibitors?
Answer: For most widely marketed H1 inhibitors (cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine), Orange Book-listed patents are either expired or limited to formulation, process, or combination patents. The most actionable risk is usually around specific dosage strengths and product forms.
What Orange Book listings typically look like for H1 brands?
Orange Book patent categories for H1 products commonly include:
- Drug substance patents (often expired)
- Drug product/formulation patents (often the last to expire)
- Method-of-use patents tied to specific regimens/indications
- Process patents for manufacturing
Featured snippet bottom line: For H1 drugs, Orange Book protection most often concentrates on the branded dosage form rather than the active ingredient.
Why dosage form matters for generic entry
- Generics must match the approved formulation strength and bioequivalence profile.
- If a brand’s remaining patents cover an extended-release mechanism, a disintegrating matrix, or a specific coated-bead design, generic approval may still be possible while infringement risk remains.
How many patents cover H1 receptor inhibitor brands, and who holds them?
Answer: The number of active, asserted patents per H1 brand is highly product-specific. In practice, the viable estate at any time tends to be a shrinking subset: formulation and combination patents that were filed for line extensions.
Typical patent holder patterns in the class
- Large legacy pharma (often original developers or line-extension owners)
- Brand successors through M&A (affecting enforcement strategy)
- Specialty formulation companies for extended-release technologies and taste-masking platforms
Patent estate strength drivers for H1 drugs
- Claim breadth (release kinetics, compositions, coating structures)
- Whether the generic’s product profile plausibly practices the claimed method/product
- Likelihood of “design-around” through formulation changes that preserve bioequivalence but avoid literal infringement
Which H1 antihistamines have been challenged via Paragraph IV, and what happened?
Answer: Paragraph IV challenges are common across H1 brands because ingredient patents expired early and remaining patents are concentrated in reformulations. Outcomes typically hinge on whether the patent at issue is formulation-specific (stronger for brand position) or broadly drafted (more vulnerable to invalidity).
Typical litigation pathways for H1 reformulation patents
- ANDA ANDA filing with Paragraph IV on a drug-product patent
- Injunction motion under 35 USC 271(e)(2)
- Settlement with non-infringement window
- Consent judgments or carve-outs by strength and dosage form
Commercial outcome pattern: When brand patents are formulation-specific and the generic can credibly change the formulation to avoid literal infringement, settlements often revolve around delayed launch timing or “at-risk” carve-outs for specific strengths.
What settlements and licensing deals shape H1 generic launch timing?
Answer: Settlement agreements in H1 tend to:
- Delay generic launch until a date tied to patent expiration or dismissal milestones
- Carve out specific strengths, NDCs, or dosage forms
- Include post-launch royalties if the generic launches earlier than a negotiated trigger
Common settlement structures for dosage-form families
- Extended-release: delayed launch for that ER mechanism while allowing immediate IR strengths.
- Pediatric formulations: delayed pediatric-specific NDCs; adult strengths may proceed earlier.
- Combination products: settlement often applies to the co-pack or fixed-dose tablet/capsule, not necessarily to monotherapy components.
Business consequence: Market access is dictated by NDC-level settlement carve-outs, not by broad “brand vs generic” headlines.
How does biosimilar risk apply to H1 receptor inhibitors?
Answer: Biosimilar risk is generally irrelevant to classical H1 receptor inhibitors because they are small-molecule drugs. Regulatory substitution is via ANDA/505(j), not BLA/351(k).
Where biologics-like risk could show up
- If a company develops a biologic targeting histamine pathways (not standard in the classic H1 class), biosimilar analysis could apply. This is not typical for H1 antihistamine therapeutics.
What formulations are protected by H1 inhibitor patents (extended release, ODT, combinations)?
Answer: Formulation protection is the main remaining patent lever. The highest-risk areas for generic entry are:
- Extended-release matrices
- Orally disintegrating tablets and fast-dissolve systems
- Combination tablets and fixed-dose regimens
- Improved solubility or bioavailability technologies
Extended-release patents: why they matter
- ER claims often define a release mechanism and composition structure that a generic may not replicate identically.
- Even if a generic achieves bioequivalence, infringement analysis can still focus on whether the generic uses the patented release pathway.
Orally disintegrating patents
- ODT claims frequently cover taste-masking and disintegration kinetics.
- If the branded ODT uses a proprietary matrix, generic “design-around” may change dissolution behavior, which can affect both bioequivalence and infringement.
Combination product patents
- Fixed-dose patents can block generic launches even after component patents expire.
- Combination patents can also expand method-of-use protection by claiming a specific dosing relationship.
How do method-of-use patents affect H1 generic labeling and “skin in the game” risk?
Answer: Method-of-use patents can create infringement exposure even when a product is bioequivalent, if the generic label instructs use in a way that practices the claimed method.
Labeling risk mechanisms under US law
- If the generic label “induces” the patented regimen, infringement risk can persist.
- Generic labels that carve out a patented regimen can reduce risk, but carve-outs can hurt commercial launch value and patient adoption.
Commercial implication: For H1 class brands, method-of-use claims can be leveraged during settlement to secure label carve-outs or launch delays.
What manufacturing and IP barriers are most relevant for H1 generics?
Answer: The most common barriers are formulation-specific manufacturing constraints and patent-protected process features for line extensions.
Manufacturing-linked patent themes
- Controlled particle size distribution and coating steps tied to dissolution profiles
- Specific excipient combinations supporting extended-release kinetics
- Process steps that ensure polymorph control and stability
Practical effect: Even where bioequivalence is feasible, engineering a “non-infringing” product can require reformulation and additional stability testing, increasing launch friction.
How does the competitive landscape look for H1 receptor inhibitors by segment?
Answer: The class is dominated by generic-led pricing in most mature oral antihistamine segments. Brand competition persists mainly in:
- Newer entrants with differentiated dosing and tolerability profiles
- Combination products with value-add positioning
- Device-adjacent delivery forms (nasal and ophthalmic) where formulation and device constraints affect generic design-around
Pricing and channel dynamics
- Pharmacy and PBM formularies drive adoption.
- For oral H1s, multiple generics with similar efficacy compress margins.
- For ophthalmic/nasal line extensions, fewer generics can reduce price compression.
Which H1 drugs have the best remaining patent leverage versus pure “ingredient-only” exposure?
Answer: Patent leverage concentrates in products with recent line extensions:
- Products with ER, ODT, or specialized solubility technologies
- Fixed-dose combinations with newly filed composition/process claims
- Products with Orange Book drug-product and method-of-use listings still active in the relevant NDCs
Featured snippet bottom line: In the H1 class, the highest-value patent estate typically aligns with a differentiated dosage form, not the underlying antihistamine molecule.
Revenue exposure: what portion of H1 brand sales is typically tied to still-protected products?
Answer: In mature H1 franchises, revenue tied to fully genericized ingredient-only SKUs is generally low relative to the total portfolio. Remaining brand sales usually track to the subset with:
- Still-listed Orange Book patents
- Formulations with fewer AB-rated competitors
- Combination SKUs with settlement-protected windows
Actionable angle: For investors or licensors, the monetizable IP is often concentrated in a small number of NDCs, which should be mapped to the current Orange Book list and recent ANDA submissions.
Key Takeaways
- H1 receptor inhibitors are mostly small molecules with expired core ingredient patents; remaining protection is typically in reformulations, combinations, and dosage-form-specific manufacturing or method-of-use claims.
- US generic entry risk is driven by the current Orange Book patent set tied to each NDC and strength, not by historical ingredient patents.
- Settlement and licensing outcomes in H1 generally hinge on NDC-level carve-outs for dosage forms (ER/ODT) and fixed-dose combinations.
- Biosimilar risk is not applicable to classical H1 antihistamines.
- The highest practical patent leverage is concentrated in differentiated dosage forms and combination SKUs with live Orange Book listings.
FAQs
1) What is the biggest driver of H1 antihistamine generic launch timing in the US?
Orange Book patent status for the exact dosage form and strength, plus whether a Paragraph IV case settles or results in an injunction.
2) Do method-of-use claims for H1 drugs block ANDA approvals?
They usually do not block approval automatically, but they can create infringement exposure through labeling and regimen practice, which drives settlements and carve-outs.
3) Which H1 dosage forms are most vulnerable to “design-around” by generics?
Immediate-release tablets and simple oral solids; extended-release and ODT systems are more likely to be formulation-patent constrained.
4) Are there meaningful patent “hotspots” in nasal antihistamine products?
Yes, formulation, particle size/solubility, and delivery system-specific patents can persist longer than ingredient-only protection.
5) How should licensors assess patent value across an H1 franchise?
Map each brand NDC to its active Orange Book listings and evaluate whether claims cover product structure, release kinetics, combination composition, or label-driven method-of-use.
References
- FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. ANDA (505(j)) and Paragraph IV Certifications. U.S. Food and Drug Administration. https://www.fda.gov/
- FDA. Drug Approval Process (NDAs and ANDAs). U.S. Food and Drug Administration. https://www.fda.gov/
More… ↓
